Experiences in a family with the Upshaw-Schulman syndrome over a 44-year period

Clin Appl Thromb Hemost. 2014 Apr;20(3):296-303. doi: 10.1177/1076029613495309. Epub 2013 Jul 19.

Abstract

A family with a novel c.717_del frameshift and a c.3655C > T missense mutation of a disintegrin and metalloproteinase with thrombospondin type I motif, member 13 protein (ADAMTS13) is described. Family members have been under observation for 44 years. Two double heterozygotes have severe early-onset Upshaw-Schulman syndrome and require prophylactic plasma infusions. Analysis reveals that 2 weekly plasma infusions are not sufficient in preventing laboratory evidence of a thrombotic thrombocytopenic purpura (TTP) attack. Both the double heterozygotes also have a heterozygous factor V Leiden G1291A mutation. One underwent splenectomy, which did not reduce the frequency of TTP episodes but resulted in a recurrent pulmonary embolism and has necessitated lifelong anticoagulant therapy. The other has mild chronic renal failure and has had episodes of atrial fibrillation and cerebral infarction. Of the 3 heterozygotes in the family, 1 has had episodes of mild thrombocytopenia.

Keywords: Upshaw-Schulman syndrome; congenital; purpura; splenectomy; therapy; thrombotic thrombocytopenic; thrombotic thrombocytopenic purpura.

Publication types

  • Case Reports

MeSH terms

  • ADAM Proteins / blood
  • ADAM Proteins / genetics
  • ADAMTS13 Protein
  • Adolescent
  • Adult
  • Female
  • Heterozygote
  • Humans
  • Male
  • Pedigree
  • Purpura, Thrombotic Thrombocytopenic / blood
  • Purpura, Thrombotic Thrombocytopenic / genetics
  • Purpura, Thrombotic Thrombocytopenic / pathology*
  • Purpura, Thrombotic Thrombocytopenic / therapy
  • Young Adult

Substances

  • ADAM Proteins
  • ADAMTS13 Protein
  • ADAMTS13 protein, human